Open AccessThis article is
- freely available
PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
First Urology Department, Medical University of Łódź, Poland
* Author to whom correspondence should be addressed.
Received: 17 May 2010; in revised form: 24 June 2010 / Accepted: 5 July 2010 / Published: 6 July 2010
Abstract: The search for the biomarkers to precisely and non-invasively characterize the biology of prostate cancer (PCa) is the focus of many laboratories across the world. Although prostate-specific antigen (PSA) remains the standard diagnostic tool for PCa, its low specificity leads to unnecessary biopsies in a substantial number of patients. More importantly, with the current status of knowledge, it is very difficult to early identify individuals with a life-threatening disease who require an immediate treatment. The significant advances in genetics and biotechnology in recent years has led to the discovery of new molecular markers including PCA3 and the TMPRSS2:ERG genomic fusion. Both PCA3 and TMPRSS2:ERG, compared to PSA, show an increased specificity in PCa detection. However, the quest for a single PCa marker that can fully satisfy urologists and their patients is still ongoing. The aim of this review is to present the recent findings on PCA3 and TMPRSS2:ERG and to describe their clinical implications and performance.
Keywords: prostate cancer; diagnosis; molecular; marker; PCA3; TMPRSS2:ERG
Citations to this Article
Cite This Article
MDPI and ACS Style
Salagierski, M.; Schalken, J.A. PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. Cancers 2010, 2, 1432-1440.
Salagierski M, Schalken JA. PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. Cancers. 2010; 2(3):1432-1440.
Salagierski, Maciej; Schalken, Jack A. 2010. "PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis." Cancers 2, no. 3: 1432-1440.